# FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer

> **NCT07446465** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Ye Xu** · enrollment: 42 (estimated)

## Conditions studied

- Colorectal Cancer (Locally Advanced or Metastatic)
- Colorectal Cancer Microsatellite Stable (MSS)

## Interventions

- **DRUG:** Serplulimab
- **DRUG:** Fruquintinib
- **DRUG:** mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)

## Key facts

- **NCT ID:** NCT07446465
- **Lead sponsor:** Ye Xu
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2027-01-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07446465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07446465, "FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT07446465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*